| Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. | |
| | |
MedLine Citation:
|
PMID: 17664467 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable. However, a prospective evaluation of clinical benefit in AGGEC patients has never before been reported in a phase III setting. PATIENTS AND METHODS: In a multinational trial (V325), 445 patients were randomly assigned and treated with either docetaxel plus cisplatin and fluorouracil (DCF) or cisplatin and fluorouracil (CF). Clinical benefit was prospectively evaluated in this trial as a secondary end point. The primary measure for clinical benefit analysis was time to definitive worsening by one or more categories of Karnofsky performance status (KPS). Secondary clinical benefit end points included time to 5% definitive weight loss, time to definitive worsening of appetite by one grade, pain-free survival (defined as time to first appearance of pain), and time to first cancer pain-related opioid intake. Clinical benefit assessments were recorded at each clinic visit. RESULTS: Clinical benefit assessments were performed in more than 75% of patients throughout V325. DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009). Although time to definitive weight loss and time to definitive worsening of appetite favored DCF, the results were not statistically significant. Pain-free survival and time to first cancer pain-related opioid intake were comparable. CONCLUSION: To our knowledge, V325 is the first phase III trial to report clinical benefit in AGGEC patients. Clinical benefit was assessed beyond protocol-specific chemotherapy. The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF. |
| | |
Authors:
|
Jaffer A Ajani; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Cindy Marabotti; Eric Van Cutsem; |
Related Documents
:
|
23444117 - Dietary total antioxidant capacity and colorectal cancer: a large case-control study in... 6647187 - Corticosteroids in terminal cancer--a prospective analysis of current practice. 23680707 - The accuracy of multi-detector row computerized tomography in staging rectal cancer com... 23386467 - Comprehensive update on the prevention and treatment of venous thromboembolism in cance... 15318957 - Descriptive study of the type and severity of decompensation caused by comorbidity in a... 12735507 - Localized prostate cancer: radiation or surgery? |
Publication Detail:
|
Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: 25 ISSN: 1527-7755 ISO Abbreviation: J. Clin. Oncol. Publication Date: 2007 Aug |
Date Detail:
|
Created Date: 2007-07-31 Completed Date: 2007-09-13 Revised Date: 2008-03-25 |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 3205-9 Citation Subset: IM |
Affiliation:
|
Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. jajani@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
drug therapy*,
pathology Adult Aged Antineoplastic Combined Chemotherapy Protocols / adverse effects, therapeutic use* Chi-Square Distribution Cisplatin / administration & dosage Drug Administration Schedule Esophageal Neoplasms / drug therapy*, pathology Fluorouracil / administration & dosage Humans Middle Aged Neoplasm Metastasis Proportional Hazards Models Prospective Studies Quality of Life Stomach Neoplasms / drug therapy*, pathology Survival Rate Taxoids / administration & dosage Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Taxoids; 114977-28-5/docetaxel; 15663-27-1/Cisplatin; 51-21-8/Fluorouracil |
| Comments/Corrections | |
Comment In:
|
J Clin Oncol. 2007 Aug 1;25(22):3188-90
[PMID:
17664464
]
Nat Clin Pract Oncol. 2008 Mar;5(3):132-3 [PMID: 18253105 ] J Clin Oncol. 2007 Dec 1;25(34):5528-9; author reply 5529-30 [PMID: 18048833 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bone marrow transplantation generates immature oocytes and rescues long-term fertility in a preclini...
Next Document: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluoroura...